Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

BMC Infectious Diseases

Table 3 Comparison of median and interquartile range (IQR) of plasma efavirenz (EFV) concentrations (mg/L) between patients who presented with any neuropsychiatric disorders (Yes) and who did not (No) during efavirenz based HAART among Ugandan HIV patients with and without TB coinfection

		Neuropsychiatric disorders			p
		No		Yes
	N	Median (IQR)	N	Median (IQR)
Day-3	37	1.61 (1.37-2.29)	125	2.29 (1.52-2.92)	0.02
week-1	28	1.86 (1.43-2.55)	80	2.26 (1.67-3.1)	0.13
week-2	40	1.69 (1.32-2.15)	111	2.22 (1.41-3.21)	0.03
week-4	40	1.57 (1.31-2.25)	110	2.49 (1.58-3.57)	0.002
week-6	36	1.8 (1.42-2.61)	86	2.37 (1.66-4.25)	0.008
week-8	45	1.64 (1.36-2.81)	121	2.31 (1.53-3.21)	0.09
week-12	41	1.84 (1.45-2.57)	101	2.57 (1.68-4.19)	0.03

Plasma efavirenz concentrations were monitored at day 3 and at 1, 2, 4, 6, 7,8 and 12 weeks after starting efavirenz based HAART. For statistical analysis, Log transformed efavirenz concentration was used using independent sample T-test.